Verve Therapeutics, Inc. (VERV)

6.66 -0.08 (-1.19%) At close: 04:00PM EDT

Verve Therapeutics, Inc.

201 Brookline Avenue
Suite 601
Cambridge, MA 02215
United States
617 603 0070
https://www.vervetx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 255

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Burt A. Adelman M.D.	Co-Founder & Independent Chairman of the Board	87.55k	N/A	1952
Dr. Sekar Kathiresan M.D.	Co-Founder, CEO & Director	899.55k	N/A	1972
Mr. Andrew D. Ashe J.D.	President, COO & General Counsel	703.85k	N/A	1967
Dr. Andrew Bellinger M.D., Ph.D.	Chief Scientific Officer	703.85k	N/A	1979
Dr. Kiran Musunuru M.D., M.P.H., Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. J. Keith Joung M.D., Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. Anthony Philippakis M.D., Ph.D.	Co-Founder & Scientific Advisory Board Member	7.97k	N/A	N/A
Dr. Barry S. Ticho FACC, M.D., Ph.D.	Co-Founder	N/A	N/A	1961
Mr. Issi Rozen M.B.A.	Co-Founder & Strategic Advisor	N/A	N/A	N/A
Ms. Allison Dorval	CFO & Principal Accounting Officer	260.93k	N/A	1976

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Verve Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.